

Can individuals with low antibody responses to vaccines against other
viruses acquire adequate SARS-CoV-2 antibody after vaccination with the
BNT162b2 mRNA vaccine?

Short title: Antibody responses to the BNT162b2 vaccine in low responders to previous
antiviral vaccines

Wataru Ogura^{1¶}, Kouki Ohtsuka^{2¶*}, Sachiko Matsuura¹, Takahiro Okuyama¹, Satsuki
Matsushima², Satoko Ymasaki², Hiroyuki Miyagi¹, Kumiko Sekiguchi¹, Hiroaki
Ohnishi², Takashi Watanabe²

¹ Department of Clinical Laboratory, Kyorin University Hospital, Mitaka, Tokyo, Japan

² Department of Laboratory Medicine, Kyorin University School of Medicine, Mitaka,
Tokyo, Japan

*Corresponding author

E-mail: kouki7@ks.kyorin-u.ac.jp (KO)

¶These authors contributed equally to this work.

Abstract

Objective

In Japan, healthcare workers (HCWs) are vaccinated against coronavirus disease (COVID-19) and other contagious viruses (measles, rubella, chickenpox, mumps, and hepatitis B) to prevent nosocomial infection. However, some do not produce sufficient antibodies after vaccination (low responders). This study investigated changes in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody levels among HCWs after SARS-CoV-2 vaccination and assessed whether low responders produced adequate SARS-CoV-2 anti-spike and neutralizing antibodies.

Methods

We conducted a prospective cohort study of HCWs before and after vaccination with the BNT162b2 mRNA vaccine in a hospital in Tokyo, Japan. The HCWs received two doses of BNT162b2 vaccine, 3 weeks apart. Those whose antibody levels against previous antiviral vaccines did not reach protective antibody levels after receiving two doses were defined as low responders, whereas those who produced adequate antibodies were defined as normal responders. SARS-CoV-2 anti-spike antibodies were measured 11 times from before the first BNT162b2 vaccination to 5 months after the second vaccination. SARS-CoV-2 neutralizing antibody activity was measured twice in low responders, 1 week to 1 month and 5 months after the second vaccination.

Results

Fifty HCWs were included in the analytic cohort. After vaccination, SARS-CoV-2 anti-spike antibody was detectable in the samples from both responders at each timepoint, but the level was lower at 5 months than at 1 week after the second

vaccination. Low responders had SARS-CoV-2 neutralizing antibody activity 1 week to 1 month after the second vaccination, which exceeded the positive threshold after 5 months.

Conclusion

After BNT162b2 vaccination, low responders acquired adequate SARS-CoV-2 anti-spike and SARS-CoV-2 neutralizing antibodies to prevent SARS-CoV-2. However, SARS-CoV-2 anti-spike antibody levels were lower at 5 months than at 1 week after the second dose of BNT162b2 vaccine in low and normal responders. Therefore, low responders should also receive a third dose of BNT162b2 vaccine.

Introduction

Coronavirus disease (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a pandemic [1–4]. In view of the high number of cases of severe illness and death due to COVID-19, vaccination against SARS-CoV-2 infection is crucial.

SARS-CoV-2 has an enveloped, single, positive-stranded RNA genome that encodes four major viral structural proteins, namely, the nucleocapsid, spike, envelope, and membrane proteins; the latter three proteins are found in its membrane. The spike protein guides viral entry into host cells by binding to angiotensin-converting enzyme 2 (ACE2) receptors, which are widely expressed on epithelial cells and macrophages [5–7] and is thus an ideal target for messenger RNA (mRNA) vaccine development.

The BNT162b2 mRNA vaccine (Pfizer–BioNTech) is highly effective at preventing clinically significant COVID-19 [8–10], reducing the incidence of asymptomatic

infection and associated infectivity [11,12], and preventing the spread of COVID-19 [9].

The BNT162b2 vaccine was the first SARS-CoV-2 vaccine to be approved in Japan, and priority vaccination of healthcare workers (HCWs) began in February 2021 in order to safeguard the medical delivery system [13].

HCWs have a high risk of infection with contagious viruses such as measles, rubella, chickenpox, mumps, and hepatitis B; therefore, in order to prevent nosocomial infections, HCWs are vaccinated against these viruses and viral antibody titers are measured [14]. Even after vaccination, some individuals do not develop adequate antibody titers against contagious viruses (low responders). It is unclear whether low responders would produce adequate SARS-CoV-2 antibodies and acquire SARS-CoV-2 neutralizing antibody activity after vaccination with the BNT162b2 vaccine. Therefore, we investigated whether low responders would acquire SARS-CoV-2 anti-spike and SARS-CoV-2 neutralizing antibody activity after vaccination with the BNT162b2 vaccine.

Materials and methods

We carried out a prospective cohort study of 50 HCWs. This study was conducted with the approval of the Ethics Committee of Kyorin University School of Medicine (Number R02-041; May 19, 2020). Informed consent was obtained from all study participants.

Subjects

The study was conducted at Kyorin University Hospital in Tokyo, Japan. HCWs at the hospital received two doses of BNT162b2 vaccine, 3 weeks apart. The participants were HCWs at the hospital who agreed to participate in the study and to periodically donate blood samples before and after vaccination. Those whose antibody levels were below the standard values for preventing infection after receiving two or more doses of vaccine against measles, rubella, chickenpox, mumps, or hepatitis B viruses, were considered as low responders.

SARS-CoV-2 anti-spike antibody assay

SARS-CoV-2 anti-spike antibody measurements were performed on serum obtained from centrifuged peripheral blood using the Elecsys Anti-SARS-CoV-2 S RUO (Roche Diagnostics International Ltd, Rotkreuz, Switzerland) on a Cobas 6000 (Roche Diagnostics) analyzer via the double-antigen sandwich enzyme-linked immunoassay method [15]. Samples were collected before the first dose of BNT162b2 vaccine was administered; 3 days after the first vaccination; 1, 2, and 3 weeks after the first vaccination; 1 week after the second vaccination; and 1, 2, 3, 4, and 5 months after the second vaccination. The measurement range of the antibody titer was 0.4–250 and ≥ 250 U/mL, measured after dilution.

SARS-CoV-2 neutralizing antibody assay

Using serum obtained from the peripheral blood of low responders after vaccination, SARS-CoV-2 neutralizing antibody activity was measured at the Osaka University Microbial Disease Research Association laboratory. A 50% inhibitory dilution factor (ID₅₀) using pseudovirus [16] was measured, and ID₅₀ values ≥ 50 were considered

positive [17]. For the neutralization assay, 60 μL of pseudovirus, which is equivalent to 2.5×10^6 relative light units (RLU)/mL, was incubated with 60 μL of serial dilutions of serum samples for 1 h at 37°C. After incubation, 100 μL of the mixture was added to the Vero cells in a 96-well plate. The cells were lysed 24 h post-infection, luciferase was activated using the Luciferase Assay System (E1501, Promega, Wisconsin, USA), and RLU were measured using a Synergy LX analyzer (BioTek, USA). Percent neutralization was calculated using GraphPad Prism 8.0.2 software (GraphPad Software, California, USA). Percentages of RLU reduction (inhibition rate) were calculated as $1 - (\text{RLU of sample sera} - \text{pseudovirus only wells}) / (\text{RLU from medium only wells} - \text{pseudovirus only wells}) \times 100\%$. The titers of neutralizing sera were calculated as ID₅₀. The transition of neutralizing antibody activity values after vaccination in low responders was examined 1 week to 1 month and 5 months after receiving the second dose of BNT162b2 vaccine.

Statistical analysis

Nonparametric continuous data are reported as median and interquartile range (IQR). The Mann–Whitney U test was used to assess whether differences between cohorts were statistically significant. Two-sided P-values <0.05 were considered statistically significant. The Wilcoxon matched-pairs signed rank test was used to assess whether differences in antibody levels within an individual at different time points were statistically significant. All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria) [18].

Specifically, EZR is a modified version of R commander (version 1.54) that has been designed to add statistical functions frequently used in biostatistics.

Results

The low responders comprised three males (L1, L2, L4) with a negative (titer <16.0) anti-measles immunoglobulin G (IgG) antibody titer after measles virus vaccination and one female (L3) with a negative (titer <4.0) anti-mumps IgG antibody titer after mumps virus vaccination. Forty-six participants, comprising 12 males and 34 females, had antiviral antibody titers after vaccination against other viruses above the standard value (normal responders). The four low responders were aged in their 20s or 40s, and all were non-smokers and non-obese. Moreover, none of them had a history of taking immunosuppressive drugs or having a disease that causes immunosuppression.

SARS-CoV-2 anti-spike antibody levels

The median (IQR) SARS-CoV-2 anti-spike antibody was 2251.5 (1639.0–3276.3) in normal responders and 3721.0 (3255.0–4983.3) in low responders 1 week after receiving the second dose of BNT162b2 vaccine. This difference was statistically significant ($P < 0.05$) (Table 1 and Fig 1A).

The median (IQR) SARS-CoV-2 anti-spike antibody in normal responders was 2251.5 (1639.0–3276.3) and 779.3 (534.6–1024.3) at 1 week and 5 months, respectively, after receiving the second dose of BNT162b2 vaccine. In low responders, the median (IQR) SARS-CoV-2 anti-spike antibody was 3721.0 (3255.0–4983.3) and

666.7 (578.9–880.6) at 1 week and 5 months, respectively, after receiving the second dose of BNT162b2 vaccine (Table 1 and Fig 1B, C).

SARS-CoV-2 anti-spike antibody was produced by both low and normal responders, but the level was lower at 5 months than at 1 week after the second vaccination (Table 1 and Fig 1A, B, C).

Table 1. SARS-CoV-2 anti-spike antibody responses in study participants before and after vaccination with the BNT162b2 mRNA vaccine according to time since vaccination and their antibody responses to previous antiviral vaccines

Time since vaccination		Normal responders (n =46)	Low responders (n =4)
		Median (IQR) U/mL	Median (IQR) U/mL
Before the first vaccination		0.4 (0.4–0.4)	0.4 (0.4–0.4)
After the first vaccination	3 days	0.4 (0.4–0.4)	0.4 (0.4–0.4)
	1 week	0.4 (0.4–0.4)	0.4 (0.4–0.4)
	2 weeks	16.9 (7.9–42.0)	18.0 (11.7–35.5)
After the second vaccination	3 weeks	74.7 (28.3–130.0)	112.7 (60.2–159.2)
	1 week	2251.5 (1639.0–3276.3)	3721.0 (3255.0–4983.3)
	1 month	1228.5 (977.7–1774.0)	1735.5 (1456.0–2121.8)
	2 months	1140.0 (845.8–1517.3)	1316.0 (1065.5–1857.5)
	3 months	983.9 (708.8–1367.0)	1008.3 (862.0–1353.3)
	4 months	912.1 (621.1–1192.8)	832.0 (741.0–1111.1)
	5 months	779.3 (534.6–1024.3)	666.7 (578.9–880.6)

The normal responders had normal antibody responses to previous antiviral vaccines.

The low responders had low antibody responses to previous measles or mumps and hepatitis B vaccines.


IQR: interquartile range

Fig 1. SARS-CoV-2 anti-spike antibody responses in study participants before and after vaccination with the BNT162b2 vaccine according to their antibody responses to previous antiviral vaccines


(A) SARS-CoV-2 anti-spike antibody responses over the whole study period from before the first dose to 5 months after the second dose of vaccine.

The box plot comparisons were performed using the Mann–Whitney U test. P-values <0.05 were considered statistically significant. Low responders had low-level antibody responses to previous measles or mumps vaccines, and normal responders had normal antibody responses to previous antiviral vaccines.


NaN; not a number



(B) SARS-CoV-2 anti-spike antibody titers in normal responders 1 week and 5 months after receiving the second dose of BNT162b2 vaccine. The antibody titers were significantly lower at 5 months than at 1 week after the second dose ($P < 0.05$).



(C) SARS-CoV-2 anti-spike antibody titers in low responders 1 week and 5 months after receiving the second dose of BNT162b2 vaccine. The antibody titers decreased, but the decrease was not statistically significant ($P = 0.068$).



SARS-CoV-2 neutralizing antibody activity in participants with low-level antibody responses to previous antiviral vaccines

SARS-CoV-2 neutralizing antibody titers were 1154.0 in L1 at 1 week after receiving the second dose of BNT162b2 vaccine and 774.2, 638.3, and 654.6 in L2, L3, and L4,

respectively, at 1 month after receiving the second dose of BNT162b2 vaccine. In the 5 months after the second vaccination, SARS-CoV-2 neutralizing antibody titers were 105.5, 147.7, 485.2, and 894.4 in L1, L2, L3, and L4, respectively. All four low responders had neutralizing antibody activity within the protective range from the 1 week to 1 month and 5 months after the second vaccination (Table 2 and Fig 2). The SARS-CoV-2 neutralizing antibody level in low responders was lower at 5 months after receiving the second dose of BNT162b2 vaccine than at 1 week to 1 month after receiving the second dose, but this difference was not statistically significant ($P = 0.27$).


Table 2. SARS-CoV-2 neutralizing antibody activity responses after the second dose of BNT162b2 vaccine in participants with low-level responses to previous antiviral vaccines

Time since the second vaccination	ID ₅₀				Median
	L1	L2	L3	L4	
1 week to 1 month	1154.0	774.2	638.3	654.6	714.4
5 months	105.5	147.7	485.2	894.4	316.5

Data are presented as 50% inhibitory dilutions (ID₅₀). L1, L2, L3, and L4 represent four separate individuals.

Fig 2. SARS-CoV-2 neutralizing antibody activity responses after the second dose of BNT162b2 vaccine in participants with low-level responses to previous antiviral vaccines

Data are presented as 50% inhibitory dilutions (ID₅₀). The dashed line indicates the cutoff for ID₅₀ [17].



Discussion

The BNT162b2 vaccine has been highly effective in preventing clinically significant COVID-19 [8–10]. However, limited information is available about the effectiveness of the BNT162b2 vaccine in individuals who have produced insufficient antibodies in response to other antiviral vaccines such as measles and mumps vaccines (low responders). In this study, in the quantitation of SARS-CoV-2 anti-spike antibody after vaccination with the BNT162b2 vaccine, SARS-CoV-2 anti-spike antibody production was confirmed in low responders, as well as in those who had had an adequate antibody response to previous antiviral vaccines.

Muik et al. [19] measured the neutralization efficacy of sera from 40 healthy German subjects immunized with the BNT162b2 vaccine and a 50% inhibitory dilution factor

using pseudovirus by the same method we used. We assumed these 40 subjects to be normal responders and compared their responses to those of the low responders in this study. The SARS-CoV-2 neutralizing activity of the low responders in this study 1 week to 1 month after receiving the second dose of BNT162b2 vaccine was comparable to that of subjects in the German study. All four low responders also developed protective levels of neutralizing antibodies. Therefore, our results confirm the findings of previous studies that have reported that vaccination with the BNT162b2 vaccine provides sufficient humoral immunity within the first month after receiving a second dose of vaccine [20].

Although neutralizing antibody activity was examined in only four participants, the SARS-CoV-2 neutralizing antibody activity value in the fifth month after the second dose of BNT162b2 vaccine did not show a significant decrease in activity compared to that 1 week to 1 month after receiving the second dose of BNT162b2 vaccine. In normal responders, the SARS-CoV-2 anti-spike antibody titer was significantly lower at 5 months after the second dose of BNT162b2 vaccine than at 1 week after the second dose. However, the decrease in antibody titers in the low responders was not statistically significant.

Antibody levels produced after measles-mumps-rubella vaccination tend to decrease almost 15 years after the first dose [21]. The SARS-CoV-2 anti-spike antibody level is known to peak and then decrease within months after the second vaccination reduced

[22,23]. In order to achieve adequate COVID-19 disease control, a third dose of SARS-CoV-2 mRNA vaccine is needed, which is already being administered in many countries [22]. Therefore, we recommend that both low and normal responders receive a third dose of BNT162b2 vaccination.

Measles, rubella, chickenpox, and mumps vaccines are live attenuated vaccines that weaken the toxicity of pathogenic microorganisms, and hepatitis B vaccines are inactivated vaccines that cause pathogenic microorganisms to lose their ability to infect [24]. Low responders do not have effective immune induction after viral vaccinations. The risk factors for low response to viral vaccines include male sex and age >40 years, smoking, obesity, chronic diseases, and genetic factors. In addition, approximately 2–10% of healthy individuals cannot raise viral antibody levels in response to viral vaccines [25,26]. Zimmermann et al. reported on factors that may affect responses to viral vaccines, including intrinsic host factors, perinatal host factors, extrinsic factors, behavioral factors, nutritional factors, environmental factors, vaccine factors, and administration factors [27]. With regard to SARS-CoV-2 anti-spike antibody production after SARS-CoV-2 vaccination, smoking has the greatest effect on SARS-CoV-2 low antibody titers after vaccination with the BNT162b2 vaccine, and antibody levels are also significantly lower values in patients with hematological malignancies [28,29]. A recent study of 658 organ transplant recipients showed that they had a lower SARS-CoV-2 anti-spike antibody response after receiving the second dose of BNT162b2 vaccine than did immunocompetent study participants [30]. Another study found that

cancer patients had a lower SARS-CoV-2 anti-spike antibody response to the BNT162b2 vaccine than did healthy individuals [31]. The low responders in this study were healthy and did not have risk factors such as an organ transplant or immunosuppression. It is unknown why they produced insufficient viral antibody after vaccination against other viruses, yet produced adequate SARS-CoV-2 anti-spike antibody after vaccination with the BNT162b2 vaccine.

The BNT162b2 vaccine is an mRNA vaccine, which incorporates mRNA encoding spike protein (antigen) on the surface of the SARS-CoV-2 into human cells, produces antigens, and uses them to induce the acquired immune system [32]. The exact factors determining the production of SARS-CoV-2 anti-spike and SARS-CoV-2 neutralizing antibody activity in low responders after receiving live attenuated or inactivated vaccinations against viruses other than SARS-CoV-2 are unknown. With live attenuated or inactivated vaccines, it is necessary for living organisms to process the weakened version of the viruses vaccinated and recognize it as an antigen, whereas with mRNA vaccines, the mRNA incorporated into the cell directly functions as a template for viral antigen. The difference in the mechanism of action of vaccines, such as the immune system being activated more efficiently, could be a factor contributing to adequate response to the BNT162b2 vaccine among participants who had previously had an inadequate response to other viral vaccines.

This study has some limitations. The number of participants was limited, and all participants were HCWs vaccinated at a single hospital. Multicenter studies with a larger sample size are needed. In individuals with low antibody response to other viral vaccines, the mechanism by which humoral immunity is acquired after mRNA vaccination needs to be clarified through future research.

In conclusion, after two doses of the BNT162b2 vaccine, both low and normal responders to previous antiviral vaccines developed adequate levels of SARS-CoV-2 anti-spike and SARS-CoV-2 neutralizing antibodies to protect against SARS-CoV-2. However, both low and normal responders had lower SARS-CoV-2 anti-spike antibody levels in the fifth month than in the first month after receiving the second dose of BNT162b2 vaccine. Therefore, a third dose of BNT162b2 vaccine should be administered to all individuals, regardless of their antibody response to previous antiviral vaccines.

Acknowledgments

We thank the HCWs of the Department of Clinical Laboratory, Kyorin University Hospital involved in the SARS-CoV-2 antibody monitoring for their valuable contribution.

References

1. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses, Baker SC, Baric RS, de Groot RJ, Drosten C, et al. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. *Nat Microbiol.* 2020;5: 536-544. doi: 10.1038/s41564-020-0695-z.
2. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. *Nature.* 2020;579: 265-269. doi: 10.1038/s41586-020-2008-3.

3. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*. 2020;579: 270-273. doi: 10.1038/s41586-020-2012-7.
4. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med*. 2020;382: 727-733. doi: 10.1056/NEJMoa2001017.
5. Song Z, Xu Y, Bao L, Zhang L, Yu P, Qu Y, et al. From SARS to MERS, Thrusting coronaviruses into the spotlight. *Viruses*. 2019;11: 59. doi: 10.3390/v11010059.
6. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell*. 2020;181: 271–280.e8. doi: 10.1016/j.cell.2020.02.052.
7. Jiang S, Lu L, Liu Q, Xu W, Du L. Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines. *Emerg Microbes Infect*. 2012;1: e13. doi: 10.1038/emi.2012.1.
8. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. *Lancet*. 2021;397: 1819-1829. doi: 10.1016/S0140-6736(21)00947-8.
9. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N Engl J Med*. 2020;383: 2603-2615. doi: 10.1056/NEJMoa2034577.

10. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. *N Engl J Med*. 2021;384: 1412-1423. doi: 10.1056/NEJMoa2101765.
11. Regev-Yochay G, Amit S, Bergwerk M, Lipsitch M, Leshem E, Kahn R, et al. Decreased infectivity following BNT162b2 vaccination: a prospective cohort study in Israel. *Lancet Reg Health Eur*. 2021;7: 100150. doi: 10.1016/j.lanepe.2021.100150.
12. Petter E, Mor O, Zuckerman N, Oz-Levi A, Younger A, Aran D, et al. Initial real world evidence for lower viral load of individuals who have been vaccinated by BNT162b2. Preprint; 2021. doi: 10.1101/2021.02.08.21251329.
13. Pharmaceuticals and Medical Devices Agency. Special Approval for Emergency on first COVID-19 vaccine in Japan [media release]; 2021. Available from: pmda.go.jp.
14. Kumakura S, Shibata H, Onoda K, Nishimura N, Matsuda C, Hirose M. Seroprevalence survey on measles, mumps, rubella and varicella antibodies in healthcare workers in Japan: sex, age, occupational-related differences and vaccine efficacy. *Epidemiol Infect*. Cambridge University Press. 2014;142: 12-19. doi: 10.1017/S0950268813000393.
15. Riestler E, Findeisen P, Hegel JK, Kabesch M, Ambrosch A, Rank CM, et al. Performance evaluation of the Roche Elecsys anti-SARS-CoV-2 S immunoassay. *J Virol Methods*. 2021;297: 114271. doi: 10.1016/j.jviromet.2021.114271.
16. Nie J, Li Q, Wu J, Zhao C, Hao H, Liu H, et al. Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. *Nat Protoc*. 2020;15: 3699-3715. doi: 10.1038/s41596-020-0394-5.

17. McMahan K, Yu J, Mercado NB, Loos C, Tostanoski LH, Chandrashekar A, et al.
Correlates of protection against SARS-CoV-2 in rhesus macaques. *Nature*.
2021;590: 630-634. doi: 10.1038/s41586-020-03041-6.
18. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for
medical statistics. *Bone Marrow Transplant*. 2013;48: 452-458. doi:
10.1038/bmt.2012.244.
19. Muik A, Wallisch AK, Sanger B, Swanson KA, Muhl J, Chen W, et al.
Neutralization of SARS-CoV-2 lineage B.1.1.7 Pseudovirus by BNT162b2 vaccine-
elicited human sera. *Science*. 2021;371: 1152-1153. doi: 10.1126/science.abg6105.
20. Adams ER, Ainsworth M, Anand R, Andersson MI, Auckland K, Baillie JK, et al.
Antibody testing for COVID-19: A report from the National COVID Scientific
Advisory Panel. *Wellcome Open Res*. 2020;5: 139. doi:
10.12688/wellcomeopenres.15927.1.
21. Bianchi FP, Stefanizzi P, De Nitto S, Larocca AMV, Germinario C, Tafuri S. Long-
term immunogenicity of measles vaccine: an Italian retrospective cohort study. *J*
Infect Dis. 2020;221: 721-728. doi: 10.1093/infdis/jiz508.
22. Israel A, Merzon E, Schaffer AA, Shenhar Y, Green I, Golan-Cohen A, et al.
Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection in a large
cohort. Preprint. medRxiv. 2021. doi: 10.1101/2021.08.03.21261496.
23. Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning
immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. *N Engl*
J Med. 2021;385: e84-e84. doi: 10.1056/NEJMoa2114583.
24. Krammer F. SARS-CoV-2 vaccines in development. *Nature*. 2020;586: 516-527.
doi: 10.1038/s41586-020-2798-3.

25. Wiedermann U, Garner-Spitzer E, Wagner A. Primary vaccine failure to routine vaccines: why and what to do? *Hum Vaccin Immunother.* 2016;12: 239-243. doi: 10.1080/21645515.2015.1093263.
26. Shem-Tov N, Yerushalmi R, Danylesko I, Litachevsky V, Levy I, Olmer L, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipients. *Br J Haematol.* 2021. doi: 10.1111/bjh.17918.
27. Zimmermann P, Curtis N. Factors that influence the immune response to vaccination. *Clin Microbiol Rev.* 2019;32: e00084-18. doi: 10.1128/CMR.00084-18.
28. Nomura Y, Sawahata M, Nakamura Y, Kurihara M, Koike R, Katsube O, et al. Age and Smoking Predict Antibody Titers at 3 Months after the Second Dose of the BNT162b2 COVID-19 vaccine. *Vaccines (Basel).* 2021;9: 1042. doi: 10.3390/vaccines9091042.
29. Herzog Tzarfati K, Gutwein O, Apel A, Rahimi-Levene N, Sadovnik M, Harel L, et al. BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies. *Am J Hematol.* 2021;96: 1195-1203. doi: 10.1002/ajh.26284.
30. Monin L, Laing AG, Muñoz-Ruiz M, McKenzie DR, Del Molino Del Barrio I, Alaguthurai T, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. *Lancet Oncol.* 2021;22: 765-778. doi: 10.1016/S1470-2045(21)00213-8.

31. Shroff RT, Chalasani P, Wei R, Pennington D, Quirk G, Schoenle MV, et al.
Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors. *Nat Med.* 2021;27: 2002-2011. doi: 10.1038/s41591-021-01542-z.
32. Mascellino MT, Di Timoteo F, De Angelis M, Oliva A. Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety. *Infect Drug Resist.* 2021;14: 3459-3476. doi: 10.2147/IDR.S315727.